Telehealth provider Hims & Hers Health (NYSE:HIMS) transitioned from a marketing high to a legal defense on February 9, 2026, as Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) filed a lawsuit alleging patent infringement and deceptive marketing
The legal action follows a high-profile Super Bowl campaign by Hims & Hers titled "Rich People Live Longer," which aimed to democratize access to expensive medications, including compounded versions of Novo’s blockbuster weight-loss drug Wegovy.
The lawsuit, filed in the wake of the "Big Game," seeks a permanent injunction and damages that Novo’s general counsel suggests could reach the "hundreds of millions."
Novo Nordisk alleges that Hims & Hers is "unlawfully mass-marketing" unapproved versions of semaglutide—the active ingredient in Wegovy and Ozempic—which the drugmaker holds under exclusive patent until 2032.
Novo claims these compounded alternatives evade the FDA's "gold standard" safety review and pose significant risks to public health.
The pressure intensified over the weekend as the Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) signaled their intent to take "swift action" against companies mass-marketing illegal copycat drugs.
On February 8, just before the lawsuit was finalized, Hims & Hers abruptly announced it would stop offering its newly launched $49-per-month compounded semaglutide pill.
The company described the retreat as a result of "constructive conversations with stakeholders," though the move coincided with an HHS referral to the Department of Justice for potential violations of the Federal Food, Drug, and Cosmetic Act.
Hims & Hers has characterized the lawsuit as an attempt by "Big Pharma" to limit consumer choice and weaponize the judicial system against personalized care.